ST2 for the Management of Heart Failure - STADE-HF
STADE-HF
Interest of ST2 to Diagnosis and Management of Patients With Heart Failure (HF)
2 other identifiers
interventional
123
1 country
1
Brief Summary
Heart failure (HF) is a severe disease, burdened with a poor prognosis (30% mortality at 2 years, 30% of rehospitalization within 1 month). It is also a major cause of health burden representing between 1.5 and 2 billions euros per year in France. Approximately 75% of these costs are due to hospitalization. Besides physical examination and echocardiography, biology may help refine the diagnosis, but also could provide powerful prognostic parameters. This study aims to assess the value of ST2 in the management of patients admitted for HF to reduce readmission at one month.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable heart-failure
Started Jan 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 31, 2016
CompletedFirst Posted
Study publicly available on registry
November 15, 2016
CompletedStudy Start
First participant enrolled
January 19, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 26, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 26, 2019
CompletedSeptember 30, 2025
October 1, 2021
2.3 years
October 31, 2016
September 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Rehospitalization
The frequence of the rehospitalization of the patient according to the treatment received
1 month
Secondary Outcomes (7)
Economic evaluation
1 month and 1 year
Mortality
1 month and 1 year
Biological markers of HF Assay
1 month and 1 year
Stay at hospital duration
1 month and 1 year
Markers of the renal function assay
1 month and 1 year
- +2 more secondary outcomes
Study Arms (2)
Conventional strategy
OTHERConventional strategy to manage the patients with HF, following the international guidelines
ST2-guided strategy
OTHERManagement of patients follow the international guidelines but are also guided by the ST2, to adapt the drugs indicated in patients with HF.
Interventions
Conventional strategy to manage the patients with HF, following the international guidelines.
patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
Eligibility Criteria
You may qualify if:
- Heart failure hospitalization
You may not qualify if:
- Other study
- Pregnancy, feeding
- Refusal
- Not possible to perform information
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Regional Hospital Arnaud de Villeneuve
Montpellier, Languedoc-Roussillon, 34295, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
François ROUBILLE, PU-PH
University Hospital, Montpellier
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2016
First Posted
November 15, 2016
Study Start
January 19, 2017
Primary Completion
April 26, 2019
Study Completion
April 26, 2019
Last Updated
September 30, 2025
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share